Been looking into weight loss options lately? You've probably come across the word "peptides".
Some are licensed medicines that have transformed how obesity is treated. Others are unlicensed compounds sold on the grey market. And the gap between the two is huge when it comes to safety, legality and whether they actually work.
This guide explains what peptides are, how they support weight loss, which treatments are available in the UK and what you need to know before considering any of them. It also covers the risks of unregulated peptide products sold online, and what genuinely helps alongside licensed treatment.
Peptides sold online as "research chemicals" are not licensed medicines. Do not inject anything that hasn't been prescribed for you.
What is a peptide?
A peptide is a short chain of amino acids, the building blocks of proteins. Your body makes peptides naturally, and uses them as signals that tell cells and organs to do specific jobs. Many hormones, enzymes and nerve messengers are peptides or proteins.
Peptides have attracted so much interest for weight loss because your body already uses them to regulate appetite, blood sugar and metabolism. Researchers have worked out which natural peptides control these processes, and found ways to copy or boost their effects with medicines.
How do peptides support weight loss?
Not all peptides support weight loss, and those that do work in different ways. The most important for weight loss are man-made peptides that mimic gut hormones your body releases after eating.
The two key ones are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). They work in overlapping but different ways.
GLP-1 is the better understood of the two. It slows how quickly food leaves your stomach, tells your brain you've eaten, and reduces cravings and the "reward" you get from food. Together, these make it much easier to eat less, without the constant hunger that makes most diets hard to stick to.
GIP's main job is to trigger insulin release when you eat, helping control your blood sugar after meals. Its role in weight loss is less clear-cut and is still being researched.
But targeting both receptors at once appears to lead to more weight loss than GLP-1 alone, which is the idea behind tirzepatide's dual action.
Feeling full sooner is the medicine working. Stop eating when you're satisfied, not when your plate is empty.
These effects don't burn fat directly. They make it easier to eat less, so you take in fewer calories. Many people also notice less "food noise", the constant thoughts about hunger and eating that make dieting so hard.
Clinical trials show that medicines that mimic GLP-1, called GLP-1 receptor agonists, can lead to meaningful weight loss alongside diet and lifestyle changes.
The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, found that adults taking semaglutide 2.4mg a week alongside lifestyle support lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo.1
Which peptides are available for weight loss in the UK?
Three peptide medicines are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight management in adults: semaglutide (Wegovy), tirzepatide (Mounjaro) and liraglutide (Saxenda).
Not every GLP-1 medicine is a peptide, though. Foundayo (orforglipron) works the same way but isn't a peptide. And some GLP-1 medicines, like Trulicity, are licensed for type 2 diabetes only.
Semaglutide (Wegovy)
Wegovy contains semaglutide, a GLP-1 receptor agonist taken as a weekly injection under the skin. Since June 2026, it's also licensed as a daily tablet.2
It's licensed for adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition, such as high blood pressure or type 2 diabetes.3
Semaglutide, the active ingredient in Wegovy and Ozempic, is also sold in a lower-dose version licensed for type 2 diabetes. Ozempic isn't licensed for weight management and shouldn't be used instead of Wegovy.
Tirzepatide (Mounjaro)
Mounjaro contains tirzepatide, which acts on both GLP-1 and GIP receptors. Targeting both at once tends to lead to more weight loss than GLP-1 alone.
The SURMOUNT-1 trial found that tirzepatide at its highest dose led to an average weight reduction of 20.9% over 72 weeks.4 Like Wegovy, it's a weekly injection and you'll need a clinical consultation to get it.
Liraglutide (Saxenda)
Saxenda is a daily injection. It's still an MHRA-licensed treatment for weight management, but many people now use the weekly options instead.5
Orforglipron (Foundayo)
Foundayo contains orforglipron, a once-daily GLP-1 tablet. Unlike the medicines above, orforglipron isn't a peptide. It's a small molecule that works on the same GLP-1 receptor.
The MHRA authorised it on 10 August 2026 for weight management and for blood sugar control in adults with type 2 diabetes.6 It isn't yet available to buy through Pharmica.
Dulaglutide (Trulicity)
Trulicity contains dulaglutide, a once-weekly GLP-1 receptor agonist licensed in the UK for type 2 diabetes. It isn't licensed for weight management.
Some weight loss is a recognised side benefit of GLP-1 medicines in people with diabetes. But if weight loss is your main aim, semaglutide and tirzepatide are the licensed options with the stronger evidence.
What unlicensed peptides are being marketed for weight loss?
Alongside licensed medicines, a range of unlicensed peptides are being sold online, often more cheaply and without a prescription. They aren't licensed by the MHRA for weight loss, and haven't been through the approval process that checks a medicine is safe, good quality and effective.
These products carry serious legal and health risks, and should never be bought or taken. The MHRA has warned that products sold without a prescription haven't been tested for safety, quality or effectiveness, and may not contain what the label says.5
Some of the peptides being marketed for weight loss include:
- Unlicensed semaglutide: sold by some online suppliers as a "research peptide" or "research chemical", often as a powder you mix yourself. These products aren't made to pharmaceutical standards, have no quality control and aren't legally authorised for human use in the UK. Read more about fake and counterfeit GLP-1 products.
- BPC-157 (Body Protective Compound-157): a man-made peptide based on a protein found in stomach juices, widely marketed for healing and fat loss. It has been studied mainly in animals and for gut conditions, and it isn't licensed by the MHRA for weight loss. Its safety and effectiveness for weight loss in people haven't been established.7
- CJC-1295 and Ipamorelin: peptides that trigger growth hormone release, often sold together with claims about growth hormone and fat loss. Neither is licensed by the MHRA for weight loss, and their quality, safety and effectiveness for this use haven't been verified.
- Retatrutide: a triple receptor agonist (GLP-1, GIP and glucagon) that is still being studied in clinical trials. The MHRA has said it isn't authorised for use in the UK, so anyone selling it is doing so illegally.5
- CagriSema: a combination of semaglutide and cagrilintide (a type of amylin analogue). It isn't licensed in the UK, so any CagriSema sold online is unlicensed and its quality, safety and effectiveness can't be verified.
- AOD-9604: a man-made fragment of human growth hormone, studied in animals for its effects on fat metabolism.8 It isn't licensed by the MHRA as a weight loss treatment.
Why are unlicensed peptides dangerous?
The risks of unregulated peptide products go beyond the lack of evidence. There are several specific concerns:
- Unknown long-term effects: licensed medicines go through years of trials and ongoing safety monitoring once they're on the market. For compounds like BPC-157 and CJC-1295, long-term safety in people hasn't been established.
- No manufacturing standards: licensed medicines are made under strict Good Manufacturing Practice (GMP) conditions, with independent testing for purity, sterility and dose accuracy. Grey market peptides have none of this. The MHRA warns that some fake weight loss injections are contaminated with bacteria and other harmful substances.5
- No dose guidance: licensed treatments start at low doses and go up gradually under clinical supervision. Unlicensed products come with no proper dosing instructions, which makes dangerous over- or under-dosing likely.
- Infection risk from self-injecting: injecting anything carries a risk of infection. That risk is much higher when the product itself may not be sterile.
- Drug interactions: GLP-1 medicines can slow how quickly your stomach empties, which may affect how other medicines are absorbed. Without a prescriber involved, these interactions can't be managed safely, especially for medicines where small changes in level matter, like warfarin.3
- Unknown effects on the heart and metabolism: peptides that trigger growth hormone release haven't been shown to be safe for weight loss, and their effects on insulin resistance and heart function in people aren't established.
Not sure if a seller is legitimate? Check they're registered with the General Pharmaceutical Council before you buy any medicine online.
If you've already taken an unlicensed product and feel unwell, get medical advice straight away.
Side effects of licensed peptides for weight loss
Even with licensed treatments, side effects are common, especially while your dose is going up. The most frequently reported are digestive:
- Nausea: very common (affects more than 1 in 10 people), usually most noticeable after a dose increase
- Vomiting
- Diarrhoea or constipation
- Tummy discomfort or bloating
These usually ease over time as your body adjusts. Licensed treatments start at the lowest dose and go up slowly to make side effects less severe.3,9
“Side effects such as nausea are common with licensed treatments, especially while your dose is going up. Tell your prescriber if you or a family member has had medullary thyroid carcinoma or MEN2. Stop the medicine and get medical help straight away if you have severe, persistent tummy pain, and do not wait for a routine appointment.
Ana Carolina GoncalvesSuperintendent Pharmacist
Less common but more serious side effects include pancreatitis (inflammation of the pancreas) and gallbladder problems.
Tell your prescriber if you or a family member has had a rare thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia type 2 (MEN2), so they can take this into account.3
Do not use weight loss medicines if you're pregnant. If you're planning a pregnancy, semaglutide should be stopped at least 2 months before, and tirzepatide at least 1 month before.3,9
Tirzepatide can make the contraceptive pill less effective. Switch to a non-oral method or add a barrier method for 4 weeks after you start and after each dose increase.9 Speak to your prescriber about breastfeeding and any other medicines you take.
What actually works alongside licensed peptide treatment for weight loss?
Licensed GLP-1 medicines are a tool, not the whole answer. The trials with the biggest weight loss results all combined medicine with structured lifestyle support. Here's what the evidence supports:
- Plenty of protein: GLP-1 medicines reduce your appetite, but they don't change what you eat, only how much. Prioritising protein at each meal helps protect your muscle while you lose weight and helps you feel full.
- Resistance exercise: a big concern with fast weight loss on GLP-1 medicines is losing muscle alongside fat. Resistance training helps protect your muscle and supports your metabolic health during and after treatment.
- Drinking enough: a lower appetite can mean drinking less too. Staying well hydrated supports digestion and helps manage nausea, one of the most common side effects of GLP-1 treatment.
Protein at every meal and two strength sessions a week are the simplest ways to protect your muscle on treatment.
Eating less also means taking in fewer vitamins and minerals. Supplements can help fill some gaps while you're in a calorie deficit:
- Complete multivitamin: a daily multivitamin gives you a nutritional safety net when you're eating much less, covering vitamins A, C, D, the B vitamins, zinc and selenium.
- Omega-3 fatty acids: EPA and DHA contribute to the normal function of the heart (the beneficial effect is obtained with a daily intake of 250mg of EPA and DHA), and DHA contributes to the maintenance of normal brain function (with a daily intake of 250mg of DHA).10 OneVit Omega-3 provides 330mg EPA and 220mg DHA per capsule, sourced from fish oil.
- Vitamin B12: especially relevant if you follow a plant-based diet, or take metformin alongside GLP-1 medicine for type 2 diabetes, as both can lower your B12 levels. OneVit Vitamin B12 contains B12 as methylcobalamin.
- Vitamin D: vitamin D deficiency is more common in people with obesity, partly because fat tissue holds on to vitamin D and makes less of it available.11 Taking a supplement is advised for most UK adults, and it's especially relevant while you're actively losing weight. Vitamin D contributes to the normal absorption and use of calcium, and vitamin K contributes to the maintenance of normal bones, which is why OneVit pairs them in its D3 and K2 formula.
These supplements don't speed up fat loss on their own. But they help support healthy, sustainable weight management and lower the risk of falling short on nutrients while you're eating less.
When to seek further advice
Stop the GLP-1 medicine and get medical help straight away if you have severe, persistent tummy pain, especially if it spreads to your back, with or without being sick. Do not wait for a routine appointment, or for the pain to be linked to meals.
Contact your GP or prescribing clinician if you:
- Have nausea or vomiting that is severe or does not settle
- Notice signs of hypoglycaemia (shakiness, sweating, confusion) if you're also taking insulin or sulfonylureas
- Are concerned about rapid muscle loss or persistent fatigue during treatment
- Have purchased or used unlicensed peptide products and are experiencing adverse effects, and seek medical advice without delay
A full list of known side effects and drug interactions is available in the patient information leaflet supplied with your medication.
Frequently asked questions
What are peptides for weight loss?
Peptides for weight loss are short chains of amino acids that influence the body's appetite, blood sugar, and metabolic signalling. In a medical context, the term most commonly refers to GLP-1 receptor agonists, which are peptide-based medicines such as semaglutide (Wegovy) and tirzepatide (Mounjaro) that mimic naturally occurring gut hormones to reduce appetite and food intake. The term is also used, more loosely, for a range of unlicensed compounds sold online. These are a different category entirely and carry significant safety risks.
Are peptides safe for weight loss?
It depends entirely on which peptide you're referring to. Licensed GLP-1 medications such as Wegovy and Mounjaro have been through extensive clinical trials and are approved by the MHRA for use in adults with obesity. They're prescribed and monitored by clinicians, and their side effects are well documented. Unlicensed peptides sold online, including compounds such as BPC-157, CJC-1295 and unregulated semaglutide, have no pharmaceutical-grade quality control and no clinically validated dosing guidance. Their safety for weight loss hasn't been established, and they may be contaminated. Do not buy or take them.
Do peptides work for weight loss?
Licensed GLP-1 peptide medications have strong clinical evidence behind them. The STEP 1 trial found semaglutide 2.4mg produced an average weight loss of 14.9% over 68 weeks, and the SURMOUNT-1 trial found tirzepatide produced an average of 20.9% at its highest dose over 72 weeks. These are among the most effective non-surgical weight loss treatments currently available. Unlicensed peptide compounds marketed for weight loss aren't licensed by the MHRA for this use, and their effectiveness and safety haven't been verified.
How do peptides work for weight loss?
Licensed weight loss peptides work by mimicking gut hormones that your body naturally releases after eating. GLP-1 receptor agonists slow gastric emptying (so you feel full for longer), signal to the brain that you've eaten, and reduce the reward response to food. This lowers appetite and eases what's often called "food noise". Tirzepatide also targets GIP receptors, which play a role in insulin regulation and appear to add to the weight loss effect. None of these mechanisms burn fat directly. They work by making it easier to eat less.
Where can I buy peptides for weight loss in the UK?
Licensed peptide-based weight loss medicines, Wegovy and Mounjaro, are available in the UK through regulated online pharmacies and GP services following a clinical consultation. They require a valid prescription and cannot legally be sold without one. Pharmica offers online consultations for these treatments and will assess your age, medical history, other medicines and treatment history before deciding whether it can supply treatment. Unlicensed peptide compounds sold on websites without a prescription are not authorised for human use in the UK. Do not buy them.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
- Medicines and Healthcare products Regulatory Agency (MHRA). First GLP-1 tablet for weight loss approved in the UK. GOV.UK; 11 June 2026. gov.uk
- Novo Nordisk Ltd. Wegovy (semaglutide) 2.4mg Summary of Product Characteristics. Electronic Medicines Compendium; 2025. medicines.org.uk/emc
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Medicines and Healthcare products Regulatory Agency (MHRA). No summer shortcut for safe weight loss. GOV.UK; 24 July 2026. gov.uk
- Pharmacy Magazine. MHRA approves second oral GLP-1, orforglipron, for weight loss. 10 August 2026. pharmacymagazine.co.uk
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. PMID:21548867
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Endocrinology. 2001;142(12):5182-9. PMID:11713213
- Eli Lilly and Company Ltd. Mounjaro KwikPen (tirzepatide) Summary of Product Characteristics. Electronic Medicines Compendium; 2026. medicines.org.uk/emc
- European Food Safety Authority (EFSA). Scientific Opinion on the substantiation of health claims related to EPA, DHA, and maintenance of normal cardiac function. EFSA Journal. 2010;8(10):1796. doi:10.2903/j.efsa.2010.1796
- Vimaleswaran KS, et al. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomisation analysis of multiple cohorts. PLOS Medicine. 2013;10(2):e1001383. doi:10.1371/journal.pmed.1001383
This article is intended for informational purposes only and does not replace professional medical advice. Always read the patient information leaflet supplied with your medication and speak to a healthcare professional if you have specific concerns.